Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Orexins/hypocretins regulate central arousal and reward pathways.
• Two receptors, OX1R and OX2R, mediate orexin signaling.
• Orexin receptor antagonists show therapeutic potential for sleep disorders.

Purpose of the Study:

• To evaluate Suvorexant (MK-4305), a dual OX1R and OX2R antagonist, as a novel insomnia therapy.
• To assess Suvorexant's receptor occupancy and sleep-promoting effects in preclinical models.

Main Methods:

• Radioligand binding assays in transgenic rats expressing human OX2R.
• Oral administration of Suvorexant in rats, dogs, and rhesus monkeys.
• Assessment of locomotor activity and sleep architecture changes.

Main Results:

• Suvorexant achieved >90% OX2R occupancy at 1.1 μM plasma exposure.
• Dose-dependent reduction in locomotor activity and promotion of sleep observed in rats, dogs, and monkeys.
• Consistent cross-species effects on sleep-wake architecture.

Conclusions:

• Suvorexant demonstrates potent dual orexin receptor antagonism.
• Cross-species efficacy supports Suvorexant's potential as an insomnia treatment.
• Dual orexin antagonists represent a promising therapeutic strategy for insomnia.